The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Official Title: Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Study ID: NCT00799825
Brief Summary: This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: Yes
GSK Investigational Site, San Diego, California, United States
GSK Investigational Site, San Francisco, California, United States
GSK Investigational Site, Denver, Colorado, United States
GSK Investigational Site, Louisville, Colorado, United States
GSK Investigational Site, Clearwater, Florida, United States
GSK Investigational Site, Miami, Florida, United States
GSK Investigational Site, West Palm Beach, Florida, United States
GSK Investigational Site, Augusta, Georgia, United States
GSK Investigational Site, Honolulu, Hawaii, United States
GSK Investigational Site, Iowa City, Iowa, United States
GSK Investigational Site, Arkansas City, Kansas, United States
GSK Investigational Site, Newton, Kansas, United States
GSK Investigational Site, Wichita, Kansas, United States
GSK Investigational Site, Bardstown, Kentucky, United States
GSK Investigational Site, Louisville, Kentucky, United States
GSK Investigational Site, Minneapolis, Minnesota, United States
GSK Investigational Site, Omaha, Nebraska, United States
GSK Investigational Site, Lebanon, New Hampshire, United States
GSK Investigational Site, Morristown, New Jersey, United States
GSK Investigational Site, Albuquerque, New Mexico, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, Poughkeepsie, New York, United States
GSK Investigational Site, Chapel Hill, North Carolina, United States
GSK Investigational Site, New Bern, North Carolina, United States
GSK Investigational Site, Cleveland, Ohio, United States
GSK Investigational Site, Tulsa, Oklahoma, United States
GSK Investigational Site, Portland, Oregon, United States
GSK Investigational Site, Carnegie, Pennsylvania, United States
GSK Investigational Site, Erie, Pennsylvania, United States
GSK Investigational Site, Erie, Pennsylvania, United States
GSK Investigational Site, Philadelphia, Pennsylvania, United States
GSK Investigational Site, Philadelphia, Pennsylvania, United States
GSK Investigational Site, Pleasant Hills, Pennsylvania, United States
GSK Investigational Site, Austin, Texas, United States
GSK Investigational Site, Houston, Texas, United States
GSK Investigational Site, Webster, Texas, United States
GSK Investigational Site, Charlottesville, Virginia, United States
GSK Investigational Site, Spokane, Washington, United States
GSK Investigational Site, Wenatchee, Washington, United States
GSK Investigational Site, Edmonton, Alberta, Canada
GSK Investigational Site, Langley, British Columbia, Canada
GSK Investigational Site, Winnipeg, Manitoba, Canada
GSK Investigational Site, St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site, Truro, Nova Scotia, Canada
GSK Investigational Site, Waterloo, Ontario, Canada
GSK Investigational Site, Beauport, Quebec, Canada
GSK Investigational Site, Gatineau, Quebec, Canada
GSK Investigational Site, Montreal, Quebec, Canada
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR